Cytek Biosciences
CTKB
125 hedge funds and large institutions have $541M invested in Cytek Biosciences in 2024 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 43 increasing their positions, 36 reducing their positions, and 4 closing their positions.
500% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 4
147% more capital inflows, than outflows
Capital inflows: $22M | Capital outflows: $8.89M
19% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 36
19% more funds holding
Funds holding: 105 → 125 (+20)
3.37% more ownership
Funds ownership: 58.23% → 61.61% (+3.4%)
57% less call options, than puts
Call options by funds: $89K | Put options by funds: $209K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DSCM
Divisadero Street Capital Management
Miami,
Florida
|
+$3.86M |
| 2 |
Voloridge Investment Management
Jupiter,
Florida
|
+$3.83M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$2.46M |
| 4 |
First Trust Advisors
Wheaton,
Illinois
|
+$1.93M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$966K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$2.8M |
| 2 |
Jane Street
New York
|
-$1.21M |
| 3 |
Barclays
London,
United Kingdom
|
-$654K |
| 4 |
JP Morgan Chase
New York
|
-$492K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$475K |
CTKB Hedge Fund Activity: Q1 2024 in Review
125 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Cytek Biosciences (CTKB) for Q1 2024, worth a combined $541M — down 25% from $720M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new CTKB positions and 4 closed out — a net gain of 20 holders — while 43 added to existing stakes and 36 trimmed.
The largest buyer was Divisadero Street Capital Management, opening a new position worth an estimated $3.86M. The largest seller was BlackRock, cutting an estimated $2.8M.
- 125 institutional investors held Cytek Biosciences (CTKB) as of Q1 2024, up from 105 in Q4 2023.
- Funds reported $541M of Cytek Biosciences stock for Q1 2024, down 25% quarter-over-quarter.
- 24 funds opened new Cytek Biosciences positions in Q1 2024 and 4 closed out, a net change of +20 holders.
- The largest Cytek Biosciences buyer in Q1 2024 was Divisadero Street Capital Management, an estimated $3.86M added.
- The largest Cytek Biosciences seller in Q1 2024 was BlackRock, an estimated $2.8M sold.
Based on aggregated 13F filings for Q1 2024.